Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome

被引：2
|
作者：
Cocorocchio, E. [1 ]
Nezi, L. [2 ]
Gandini, S. [2 ]
Manzo, T. [2 ]
Mazzarella, L. [2 ]
Lotti, F. [2 ]
Pala, L. [3 ]
Gnagnarella, P. [2 ]
Conforti, F. [3 ]
Pennacchioli, E. [4 ]
Fierro, M. T. [5 ]
Ribero, S. [6 ]
Senetta, R. [5 ]
Picciotto, F. [7 ]
Caliendo, V. [7 ]
Quaglino, P. [5 ]
Mazzarol, G. [3 ,8 ]
Orsolini, G. M. [4 ]
Prestianni, P. [4 ]
Ferrucci, P. F. [9 ]
机构：
[1] IRCCS, Ist Europeo Oncol, Hematoncol, Milan, Italy
[2] IRCCS, Ist Europeo Oncol, Experimental Oncol, Milan, Italy
[3] IRCCS, Ist Europeo Oncol, Med Oncol Melanoma Sarcoma & Rare Tumors, Milan, Italy
[4] IRCCS, Ist Europeo Oncol, Sarcoma & Rare Tumors, Surg Melanoma, Milan, Italy
[5] AOU Citta Salute & Sci Torino, Med Sci, Turin, Italy
[6] Azienda Osped Univ San Giovanni Battista Torino, Med Sci Dept, Turin, Italy
[7] AOU Citta Salute & Sci Torino Turin, Dermatol Surg, Turin, Italy
[8] IRCCS, Ist Europeo Oncol, Pathol & Lab Med, Milan, Italy
[9] IRCCS, Ist Europeo Oncol, Oncol Dept, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1457
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1072P
引用
收藏
页码：S889 / S890
页数：2
相关论文
共 50 条
  • [11] Nivolumab plus Ipilimumab in Advanced Melanoma
    Wolchok, Jedd D.
    Kluger, Harriet
    Callahan, Margaret K.
    Postow, Michael A.
    Rizvi, Naiyer A.
    Lesokhin, Alexander M.
    Segal, Neil H.
    Ariyan, Charlotte E.
    Gordon, Ruth-Ann
    Reed, Kathleen
    Burke, Matthew M.
    Caldwell, Anne
    Kronenberg, Stephanie A.
    Agunwamba, Blessing U.
    Zhang, Xiaoling
    Lowy, Israel
    Inzunza, Hector David
    Feely, William
    Horak, Christine E.
    Hong, Quan
    Korman, Alan J.
    Wigginton, Jon M.
    Gupta, Ashok
    Sznol, Mario
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02): : 122 - 133
  • [12] Nivolumab plus Ipilimumab in Advanced Melanoma
    Santhosh, Akhil
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (12): : 1245 - 1246
  • [13] Ipilimumab plus nivolumab for advanced melanoma
    Hassel, Jessica C.
    LANCET ONCOLOGY, 2016, 17 (11): : 1471 - 1472
  • [14] Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma
    Carreau, Nicole A.
    Pavlick, Anna C.
    FUTURE ONCOLOGY, 2019, 15 (04) : 349 - 358
  • [15] Preliminary results of a Neoadjuvant combo-immunotherapy with ipilimumab and nivolumab in locally advanced or limited metastatic melanoma
    Ferrucci, Pier Francesco
    Pala, Laura
    Conforti, Fabio
    Nezi, Luigi
    Manzo, Teresa
    Cocorocchio, Emilia
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18
  • [16] Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab
    Tahsin M. Khan
    Martha E. Teke
    Giorgos C. Karakousis
    John T. Miura
    Robert M. Brody
    Jonathan M. Hernandez
    Tara C. Mitchell
    Annals of Surgical Oncology, 2022, 29 : 2771 - 2772
  • [17] Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Grob, Jean-Jacques
    Rutkowski, Piotr
    Lao, Christopher D.
    Cowey, C. Lance
    Schadendorf, Dirk
    Wagstaff, John
    Dummer, Reinhard
    Ferrucci, Pier Francesco
    Smylie, Michael
    Butler, Marcus O.
    Hill, Andrew
    Marquez-Rodas, Ivan
    Haanen, John B. A. G.
    Guidoboni, Massimo
    Maio, Michele
    Schoffski, Patrick
    Carlino, Matteo S.
    Lebbe, Celeste
    McArthur, Grant
    Ascierto, Paolo A.
    Daniels, Gregory A.
    Long, Georgina, V
    Bas, Tuba
    Ritchings, Corey
    Larkin, James
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 127 - +
  • [18] Nivolumab plus ipilimumab in the treatment of advanced melanoma
    Tsai, Katy K.
    Daud, Adil I.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [19] Nivolumab plus ipilimumab in the treatment of advanced melanoma
    Katy K. Tsai
    Adil I. Daud
    Journal of Hematology & Oncology, 8
  • [20] Adjuvant Nivolumab or Ipilimumab plus Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab
    Khan, Tahsin M.
    Teke, Martha E.
    Karakousis, Giorgos C.
    Miura, John T.
    Brody, Robert M.
    Hernandez, Jonathan M.
    Mitchell, Tara C.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (05) : 2771 - 2772
12345